Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 3/20 | 0.80 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.80 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.80 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.74 |
| ▸ | TP53 | P04637 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217118 | 0.92 | TNF (0.68) | TNFNOD2NOD1PTPN11TP53 | |
| SCHEMBL23217195 | 0.90 | TNF (0.71) | TNFNOD2NOD1PTPN11LMNA | |
| SCHEMBL23217304 | 0.89 | TNF (0.71) | TNFNOD2NOD1PTPN11MAPK1 | |
| SCHEMBL17225898 | 0.89 | PTPN11 (0.80) | PTPN11 | |
| SCHEMBL23217307 | 0.88 | TNF (0.70) | TNFNOD2NOD1PTPN11MAPK1 | |
| SCHEMBL23217035 | 0.88 | TNF (0.75) | TNFNOD2NOD1PTPN11TP53 | |
| SCHEMBL23217306 | 0.87 | TNF (0.74) | TNFNOD2NOD1PTPN11TP53 | |
| SCHEMBL23217301 | 0.87 | PTPN11 (0.67) | TNFNOD2NOD1PTPN11LMNA | |
| SCHEMBL23217031 | 0.87 | TNF (0.67) | TNFNOD2NOD1PTPN11TP53 | |
| SCHEMBL12372326 | 0.86 | PTPN11 (0.83) | PTPN11TP53POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2021072369-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072369-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | CFH, LPAR3, CBR3 | TNF 4748/4885NOD2 1295/4885NOD1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.